FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population
FCGR3A presents a single nucleotide polymorphism at location 158 (V/F), which affects its binding to the fragment crystallizable (Fc) of antibodies (Abs). FcγRIIIa-158 V allotype has the highest affinity and is associated with a better clinical response to IgG1 monoclonal Abs (mAb) treatment. We com...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2388306 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846142265070714880 |
|---|---|
| author | Michaël Constantinides Nicolas Robert Caroline Multrier Loïs Coënon Mauricio Campos-Mora Carine Jacquard Fei Gao Sara Zemiti Jessy Presumey Guillaume Cartron Jérome Moreaux Martin Villalba |
| author_facet | Michaël Constantinides Nicolas Robert Caroline Multrier Loïs Coënon Mauricio Campos-Mora Carine Jacquard Fei Gao Sara Zemiti Jessy Presumey Guillaume Cartron Jérome Moreaux Martin Villalba |
| author_sort | Michaël Constantinides |
| collection | DOAJ |
| description | FCGR3A presents a single nucleotide polymorphism at location 158 (V/F), which affects its binding to the fragment crystallizable (Fc) of antibodies (Abs). FcγRIIIa-158 V allotype has the highest affinity and is associated with a better clinical response to IgG1 monoclonal Abs (mAb) treatment. We compared the allele frequency of FCGR3A-F158V polymorphism in cohorts of patients with B-cell lymphoproliferative disorders, including multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), non-Hodgkin lymphoma (NHL), and B-cell chronic leukemia (B-CLL). FCGR3A-158F homozygous were enriched and tended to be in MM and MGUS patients, respectively; but neither in B-CLL nor in NHL patients. We identified a significantly lower concentration of CD8 T-cells and resting memory CD4 T-cells in MM patients bone marrow with the F/F genotype, associated with an increase in the macrophage percentage. In contrast, natural killer cells increased in V/V homozygous patients. This suggests a deregulation of the immune microenvironment in FCGR3A-F/F homozygous patients. However, we did not observe difference in response following treatment combining chemotherapy associated or not with daratumumab, an IgG1 mAb direct against CD38. Our findings suggest that FCGR3A F158V polymorphism can regulate the immune environment and affect the development of tumor plasma cells. |
| format | Article |
| id | doaj-art-41bd2ee094e54a0abe73a44b834b684b |
| institution | Kabale University |
| issn | 2162-402X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-41bd2ee094e54a0abe73a44b834b684b2024-12-03T13:49:34ZengTaylor & Francis GroupOncoImmunology2162-402X2024-12-0113110.1080/2162402X.2024.2388306FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy populationMichaël Constantinides0Nicolas Robert1Caroline Multrier2Loïs Coënon3Mauricio Campos-Mora4Carine Jacquard5Fei Gao6Sara Zemiti7Jessy Presumey8Guillaume Cartron9Jérome Moreaux10Martin Villalba11IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceDepartment of Biological Hematology, CHU Montpellier, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceDepartment of Clinical Hematology, CHU Montpellier, Montpellier, FranceDepartment of Biological Hematology, CHU Montpellier, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceFCGR3A presents a single nucleotide polymorphism at location 158 (V/F), which affects its binding to the fragment crystallizable (Fc) of antibodies (Abs). FcγRIIIa-158 V allotype has the highest affinity and is associated with a better clinical response to IgG1 monoclonal Abs (mAb) treatment. We compared the allele frequency of FCGR3A-F158V polymorphism in cohorts of patients with B-cell lymphoproliferative disorders, including multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), non-Hodgkin lymphoma (NHL), and B-cell chronic leukemia (B-CLL). FCGR3A-158F homozygous were enriched and tended to be in MM and MGUS patients, respectively; but neither in B-CLL nor in NHL patients. We identified a significantly lower concentration of CD8 T-cells and resting memory CD4 T-cells in MM patients bone marrow with the F/F genotype, associated with an increase in the macrophage percentage. In contrast, natural killer cells increased in V/V homozygous patients. This suggests a deregulation of the immune microenvironment in FCGR3A-F/F homozygous patients. However, we did not observe difference in response following treatment combining chemotherapy associated or not with daratumumab, an IgG1 mAb direct against CD38. Our findings suggest that FCGR3A F158V polymorphism can regulate the immune environment and affect the development of tumor plasma cells.https://www.tandfonline.com/doi/10.1080/2162402X.2024.2388306FCGR3A polymorphismFcγRIIIa/CD16amonoclonal gammopathy of undetermined significance (MGUS)multiple myeloma (MM)tumor environment |
| spellingShingle | Michaël Constantinides Nicolas Robert Caroline Multrier Loïs Coënon Mauricio Campos-Mora Carine Jacquard Fei Gao Sara Zemiti Jessy Presumey Guillaume Cartron Jérome Moreaux Martin Villalba FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population OncoImmunology FCGR3A polymorphism FcγRIIIa/CD16a monoclonal gammopathy of undetermined significance (MGUS) multiple myeloma (MM) tumor environment |
| title | FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population |
| title_full | FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population |
| title_fullStr | FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population |
| title_full_unstemmed | FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population |
| title_short | FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population |
| title_sort | fcgr3a f158v alleles frequency differs in multiple myeloma patients from healthy population |
| topic | FCGR3A polymorphism FcγRIIIa/CD16a monoclonal gammopathy of undetermined significance (MGUS) multiple myeloma (MM) tumor environment |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2388306 |
| work_keys_str_mv | AT michaelconstantinides fcgr3af158vallelesfrequencydiffersinmultiplemyelomapatientsfromhealthypopulation AT nicolasrobert fcgr3af158vallelesfrequencydiffersinmultiplemyelomapatientsfromhealthypopulation AT carolinemultrier fcgr3af158vallelesfrequencydiffersinmultiplemyelomapatientsfromhealthypopulation AT loiscoenon fcgr3af158vallelesfrequencydiffersinmultiplemyelomapatientsfromhealthypopulation AT mauriciocamposmora fcgr3af158vallelesfrequencydiffersinmultiplemyelomapatientsfromhealthypopulation AT carinejacquard fcgr3af158vallelesfrequencydiffersinmultiplemyelomapatientsfromhealthypopulation AT feigao fcgr3af158vallelesfrequencydiffersinmultiplemyelomapatientsfromhealthypopulation AT sarazemiti fcgr3af158vallelesfrequencydiffersinmultiplemyelomapatientsfromhealthypopulation AT jessypresumey fcgr3af158vallelesfrequencydiffersinmultiplemyelomapatientsfromhealthypopulation AT guillaumecartron fcgr3af158vallelesfrequencydiffersinmultiplemyelomapatientsfromhealthypopulation AT jeromemoreaux fcgr3af158vallelesfrequencydiffersinmultiplemyelomapatientsfromhealthypopulation AT martinvillalba fcgr3af158vallelesfrequencydiffersinmultiplemyelomapatientsfromhealthypopulation |